AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers.
Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.
AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables AdvanCell to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials.
“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers. It is especially pleasing to continue and expand our existing relationship.”
Jacob Van Naarden, President of Lilly Oncology, added, “Partnering with AdvanCell aligns with our commitment to advancing innovative radiopharmaceuticals. We are excited to explore the potential of Pb-212-based alpha therapies as we work to bring meaningful new treatments for patients.”
Financial terms of the agreement were not disclosed.
About AdvanCell
AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for cancer patients globally. For more information, visit www.advancell.com.au.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210990350/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IonQ Partners with Italy’s National Strategy for Quantum Technology; Co-Founds Q-Alliance to Jointly Create Quantum Hub20.10.2025 13:05:00 CEST | Press release
Q-Alliance launch marks a key milestone in Italy’s digital transformation and the country’s ambitious quantum ecosystem goals IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance brings together public and private partners committed to building a future-forward quantum ecosystem. The initiative – launched at the ComoLake2025 Digital Innovation Forum – combines the advanced quantum technology and expertise of IonQ with support from leading Italian scientific institutions and governmental stakeholders. Q-Alliance aims to accelerate breakthroughs in science, support Italy’s industrial transition, and ensure long-term digital sovereignty. “IonQ enables a fantastic opportunity for Italy to lead a ‘Quantum Renaissance’ with the potential to transf
Cooler Master Expands Its Thermal Excellence with Hyper 212 3DHP Series and V4 Alpha 3DHP Black20.10.2025 12:01:00 CEST | Press release
Reliable, Quiet Single-Tower Air Coolers Built on Patented 3DHP Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced availability of the Hyper 212 3DHP series and the V4 Alpha 3DHP Black air coolers. Both use Cooler Master’s patented 3DHP Technology the company’s latest cooling innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020694683/en/ The new air coolers from Cooler Master: the Hyper 212 3DHP series and the V4 Alpha 3DHP Black. “With 3DHP, we move past pipe-count and focus on results,” said Matteo Stracciari, GM of Cooler Master EU. “Less heat. More dependable performance. Less noise. More long-term reliability. All in compact single-tower builds.” 3DHP: Less is More 3DHP reengineers the heat pipe itself for better evaporation, condensation, and flow. A third pipe endpoint and a precision T-joint increase heat pickup and flow, turning fewer pipes into more effective
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 202520.10.2025 12:00:00 CEST | Press release
New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLCEarly data from investigational HPK1 inhibitor BGB-26808, in combination with TEVIMBRA, show promise in advanced solid tumors BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October 17-21. The results reinforce TEVIMBRA’s consistent and durable efficacy across lung cancer subtypes, including non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC). In addition, the first clinical data from BeOne’s investigational HPK1 inhibitor, BGB-26808, as a single agent and in combination with TEVIMBRA, will b
SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB520.10.2025 11:00:00 CEST | Press release
SunRock Biopharma, a biotechnology company focused on developing next-generation therapeutic antibodies, and Chime Biologics, a global leading contract development and manufacturing organization (CDMO), today announced a strategic collaboration for the development of SRB5, a novel anti-CCR9 monoclonal antibody targeting inflammatory bowel disease (IBD), with potential expansion into other immune-mediated inflammatory indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251019831972/en/ The scientific team of SunRock Biopharma. SRB5 is a humanized monoclonal antibody with enhanced ADCC properties, designed to selectively deplete CCR9+ cells involved in chronic intestinal inflammation. It is the latest advancement in SunRock’s anti-CCR9 platform and represents a significant advance in a selective therapeutic approach for treating diseases such as Crohn’s disease and ulcerative colitis. Through this partnership, SunRock
New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EURneffy®, Now Available in the UK20.10.2025 10:01:00 CEST | Press release
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020480135/en/ EURneffy® 2 mg nasal spray offers a simple-to-use,3,4 pocket-sized alternative to traditional AAIs, with the potential to transform the lives of those with severe allergies in the UK. It is designed to be portable and ready-to-use in emergencies,3 offering a new alternative to traditional AAIs, including for those who struggle with needles or need a more convenient option they can rely on. EURneffy® also has a longer shelf life and can withstand temperature changes better than traditional AAIs,3,5 meaning fewer trips to the GP for a new prescription. Simon Williams, Ch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom